Leukemia

Trial Protocol ID
USOR 24089_M24-287

Investigator
Vinni Juneja, MD

A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)

Learn More